ESMO Congress 2012

Gastrointestinal Cancers

28 Sep - 02 Oct 2012, Vienna, Austria

ESMO 2012 Congress

Please find below the links to all ESMO 2012 presentations that have an abstract, poster, slide set or webcast. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Search Meeting Resources by Keyword

 

 

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...novel-surgical-approach-to-thyroid-neoplasms

Background Kochers' anterior approach is the universal standard for thyroidectomy but with several complications. Feasibility of horizontal lateral thyroidectomy (Thomas' Technique,) based on 3 D...

Date: 28 Sep 2012
Presenter: Thomas Varughese
Resources: Abstract
Topics: Thyroid Cancer, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...d-safety-profile-from-a-patient-access-study

Introduction and research objectives Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE; mifamurtide) is approved for treatment of non-metastatic osteosarcoma (OS) in Europe, Israel, and Mexico.

Date: 29 Sep 2012
Presenter: Peter Anderson
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Bone Sarcomas

http://oncologypro.esmo.org/Meeting-Resourc...ab-BEV-chemotherapy-CT-for-ovarian-cancer-OC

Background BEV significantly improved the efficacy of front-line CT for OC in the ICON7 and GOG-0218 phase III trials. The global single-arm ROSiA study was designed to assess the safety of BEV-containing...

Date: 29 Sep 2012
Presenter: Cesar Mendiola
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Ovarian Cancer

http://oncologypro.esmo.org/Meeting-Resourc...h-risk-of-recurrent-renal-cell-carcinoma-RCC

Background Surgical resection alone may fail to cure high-risk RCC. Progression to metastatic recurrence directly relates to tumor size in subjects with clinically localized RCC, and 25–50% of subjects...

Date: 29 Sep 2012
Presenter: Alain Ravaud
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Renal Cell Cancer

http://oncologypro.esmo.org/Meeting-Resourc...pancreatic-cancer-in-Asia-results-of-phase-I

Introduction NC-6004 is a cisplatin-incorporated polymeric micelle with a size of 30 nm in diameter composed of polyethylene glycol-polyglutamic acid block co-polymer via polymer-metal complex formation.

Date: 30 Sep 2012
Presenter: Wu-Chou Su
Resources: Abstract
Topics: Drug Development, Pancreatic Cancer

http://oncologypro.esmo.org/Meeting-Resourc...noma-HCC-a-single-center-retrospective-study

Background Combining sorafenib with chemotherapy can potentially provide a new regime with enhanced benefit. Phase II study has demonstrated promising activity in combining sorafenib, oxaliplatin and...

Date: 30 Sep 2012
Presenter: Joanne Chiu
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...s-with-advanced-hepatocellular-carcinoma-HCC

Background Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFR�. The inherent vascularity of HCC makes it a target for VEGF inhibitors and other molecular...

Date: 30 Sep 2012
Presenter: Kenji Ikeda
Resources: Abstract
Topics: Drug Development, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...s-with-early-HER2-positive-breast-cancer-EBC

Purpose One year of H-based therapy, consisting of 18 q3w cycles, is standard of care for the adjuvant treatment of HER2-positive EBC. H is administered intravenously (IV) over 30–90 mins.

Date: 01 Oct 2012
Presenter: Joseph Gligorov
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Breast Cancer, Early Stage

http://oncologypro.esmo.org/Meeting-Resourc...lly-advanced-or-metastatic-breast-cancer-MBC

Background T-DM1 is an antibody–drug conjugate incorporating the HER2–targeted antitumor properties of trastuzumab (T) with the cytotoxic activity of the microtubule inhibitor DM1, conjugated by a stable linker.

Date: 01 Oct 2012
Presenter: Sunil Verma
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Breast Cancer, Metastatic

http://oncologypro.esmo.org/Meeting-Resourc...-carcinoma-mRCC-Results-of-the-COMPARZ-trial

Background: Pazopanib and sunitinib are oral multi-kinase angiogenesis inhibitors that have shown progression-free survival (PFS) benefit for mRCC patients in clinical trials (NEJM 2007;356:115; JCO 2009;29:475).

Date: 01 Oct 2012
Presenter: Robert Motzer
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Renal Cell Cancer